NK cell is in PBMC with a range of 5–20 %. Therefore, various protocols have been used to isolate and preferentially expand primary NK cells from PBMC [
50]. The common principle is a combination of cell selection and depletion using immunomagnetic beads [
52]. These protocols use leukapheresis products for the clinical-grade purification of NK cells by depleting CD3 cells followed by selection of CD56 cells [
28] or in combination with subsequent short-term (14-day) expansion with IL-2 [
52]. Clinical-grade expansion of NK cells in lymphokine-activated killer (LAK) cell cultures for 28 days with IL-15 has been reported [
27]. NK cell expansion requires multiple signals for survival, proliferation and activation. Thus, expansion strategies have been focused either to substitute these factors using autologous feeder cells and/or to use genetically modified allogeneic feeder cells Functional activity is defined by cytotoxicity against various malignant cell lines and expression pattern of NK cell receptor (cluster of differentiation (CD)-16, natural killer group-2 member D (NKG2D), CD69, NKp30, NKp44, NKp46 and CD158b. Expansion of NK with autologous PBMC as feeder cells has been shown to generate functional active NK cells with a therapeutic cells dosage [
54]. Using GMP-compliant components and autologous feeder cells, purified NK cells were effectively expanded (2500-fold at day 17) [
54]. Similarly, large-scale expansion of GMP-compliant NK cells with cytolytic activity against tumor cells has been reported using autologous PBMCs in the presence of OKT3 and IL-2 at 14 day [
55]. Other feeder cells such as Jurkat T-lymphoblast subline KL-1 have been used which achieved expansion of NK cells accompanied by reciprocal inhibition of T-cell growth [
56]. Promising results were also obtained by the leukemia cell line K562, genetically altered to express membrane-bound form of IL-15 and the 4-1BB (CD137L), which has led to an 277-fold expansion after 3 weeks (21 days) in culture [
57]. More recently, K562 cell lines have been engineered to express membrane-bound IL-21 along with CD137L [
58]. Expansion was highly selectively for NK cells and reached 100-fold by 3 weeks while CD3+ T cells went from initially 60–1 %. [
59]. Genetically modified K562 feeder cells have also the benefit to be used as frozen stock (vials) [
60]. In addition to the expansion of total NK cells, strategies for selective expansion of individual NK cell subpopulations have been developed. These strategies are based on the observation that despite a fixed number of inherited KIR genes, each individual NK cell expresses a different number of KIR genes on the cell surface [
61]. NK cells with particular sets of inhibitory receptors have been named ‘single-KIR’ cells in the context of developing KIR mismatched cell components for therapeutic use. ‘Single-KIR’ NK cells have been shown to lysis human acute myeloid leukemia (AML) cells in vitro and in vivo [
62,
63]. Selection and expansion of clinical-grade single-KIR+ NK cell subsets have been established using a GMP-based approach [
63].